Insider · CIK 0001951287

Karas Eric

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001951287

Forms 4 and 5

Insider transactions

29 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-12	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+25K sh	$1.50	+$37.5K	37,176
2026-06-12	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−25K sh	$10.00	−$250K	12,176
2026-06-12	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−25K sh	—	—	519,588
2026-01-02	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Commercial Officer	AAward	+240K sh	—	—	240,000
2025-07-01	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+15K sh	$1.50	+$22.5K	25,315
2025-07-01	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−15K sh	$16.99	−$255K	10,315
2025-07-01	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−15K sh	—	—	544,588
2025-06-18	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+15K sh	$1.50	+$22.5K	22,696
2025-06-18	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−15K sh	$16.00	−$240K	7,696
2025-06-18	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−15K sh	—	—	559,588
2025-03-20	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+10K sh	$1.50	+$15K	17,696
2025-03-20	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−10K sh	$14.00	−$140K	7,696
2025-03-20	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−10K sh	—	—	574,588
2025-01-02	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Commercial Officer	AAward	+152K sh	—	—	152,300
2024-12-04	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+6,283 sh	$1.50	+$9,424.5	11,976
2024-12-04	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−6,283 sh	$14.00	−$88K	5,693
2024-12-04	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−6,283 sh	—	—	584,588
2024-12-02	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+3,717 sh	$1.50	+$5,575.5	9,410
2024-12-02	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−3,717 sh	$14.11	−$52.5K	5,693
2024-12-02	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,717 sh	—	—	590,871
2024-09-18	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+10K sh	$1.50	+$15K	15,693
2024-09-18	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−10K sh	$14.00	−$140K	5,693
2024-09-18	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−10K sh	—	—	594,588
2024-08-19	SPRYARS Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+10K sh	$1.50	+$15K	15,693
2024-08-19	SPRYARS Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−10K sh	$14.00	−$140K	5,693
2024-08-19	SPRYARS Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−10K sh	—	—	604,588
2024-01-02	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Commercial Officer	AAward	+200K sh	—	—	200,000
2023-01-03	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Commercial Officer	AAward	+50K sh	—	—	50,000
2022-11-08	SPRYARS Pharmaceuticals, Inc. · Stock option (right to buy)A Award	Chief Commercial Officer	AAward	+615K sh	—	—	614,588

Recent filings

Accepted (ET)
Jun 124
Karas Eric0001951287-26-000004
SEC(opens sec.gov)
Jan 54
Karas Eric0001951287-26-000002
SEC(opens sec.gov)
Jul 34
Karas Eric0001415889-25-019321
SEC(opens sec.gov)
Jun 204
Karas Eric0001415889-25-017901
SEC(opens sec.gov)
Mar 214
Karas Eric0001415889-25-008796
SEC(opens sec.gov)
Jan 34
Karas Eric0001415889-25-000459
SEC(opens sec.gov)
Dec 44
Karas Eric0001415889-24-028349
SEC(opens sec.gov)

Companies

ARS Pharmaceuticals, Inc.Chief Commercial OfficerSPRY

Address

C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 300

SAN DIEGO, CA, 92130